Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery
Status:
Completed
Trial end date:
2015-08-27
Target enrollment:
Participant gender:
Summary
This randomized phase III trial studies sunitinib malate to see how well it works compared to
sorafenib tosylate or placebo in treating patients with kidney cancer that has been removed
by surgery. Sunitinib malate and sorafenib tosylate may stop the growth of tumor cells by
blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
Giving sunitinib malate or sorafenib tosylate after surgery may kill any tumor cells that
remain after surgery. It is not yet known whether sunitinib malate is more effective than
sorafenib tosylate or placebo in treating kidney cancer.
Phase:
Phase 3
Details
Lead Sponsor:
National Cancer Institute (NCI)
Collaborators:
Cancer and Leukemia Group B ECOG-ACRIN Cancer Research Group NCIC Clinical Trials Group Southwest Oncology Group